MA55909A - Inhibiteurs de cdk - Google Patents

Inhibiteurs de cdk

Info

Publication number
MA55909A
MA55909A MA055909A MA55909A MA55909A MA 55909 A MA55909 A MA 55909A MA 055909 A MA055909 A MA 055909A MA 55909 A MA55909 A MA 55909A MA 55909 A MA55909 A MA 55909A
Authority
MA
Morocco
Prior art keywords
cdk inhibitors
cdk
inhibitors
Prior art date
Application number
MA055909A
Other languages
English (en)
Inventor
Hu He
Zhilong Hu
Fei Zhang
Wenge Zhong
Xiaotian Zhu
Original Assignee
Qilu Regor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Regor Therapeutics Inc filed Critical Qilu Regor Therapeutics Inc
Publication of MA55909A publication Critical patent/MA55909A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
MA055909A 2019-05-05 2020-05-05 Inhibiteurs de cdk MA55909A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2019085494 2019-05-05

Publications (1)

Publication Number Publication Date
MA55909A true MA55909A (fr) 2022-03-16

Family

ID=73051265

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055909A MA55909A (fr) 2019-05-05 2020-05-05 Inhibiteurs de cdk

Country Status (18)

Country Link
US (9) US20220296595A1 (fr)
EP (2) EP3966213A4 (fr)
JP (4) JP7671425B2 (fr)
KR (2) KR20260004524A (fr)
CN (4) CN114364675A (fr)
AU (4) AU2020269469B2 (fr)
BR (1) BR112021022105A2 (fr)
CA (1) CA3138973A1 (fr)
CL (1) CL2021002903A1 (fr)
CO (1) CO2021016504A2 (fr)
EA (1) EA202193015A1 (fr)
IL (2) IL315588A (fr)
MA (1) MA55909A (fr)
MX (4) MX2021013531A (fr)
PH (1) PH12021552805A1 (fr)
SG (1) SG11202112229UA (fr)
TW (4) TWI875756B (fr)
WO (2) WO2020224568A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126731A1 (fr) 2017-12-22 2019-06-27 Petra Pharma Corporation Dérivés d'aminopyridine utilisés en tant qu'inhibiteurs de la phosphatidylinositol phosphate kinase
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
MA55909A (fr) * 2019-05-05 2022-03-16 Qilu Regor Therapeutics Inc Inhibiteurs de cdk
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
US20230416221A1 (en) * 2020-11-20 2023-12-28 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Dihydroisoquinolinone and isoindolinone derivatives and uses thereof
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023143482A1 (fr) * 2022-01-29 2023-08-03 上海辉启生物医药科技有限公司 Composé ou sel de 2-aminopyrimidine, son procédé de préparation et son utilisation
CN119137102A (zh) * 2022-04-08 2024-12-13 拜奥列司治疗有限公司 Cdk9抑制剂
WO2024051702A1 (fr) * 2022-09-05 2024-03-14 浙江同源康医药股份有限公司 Composé utilisé comme inhibiteur de la kinase cdk4 et son utilisation
EP4618755A1 (fr) * 2022-11-15 2025-09-24 Larkspur Biosciences, Inc. Inhibiteurs et agents de dégradation de protéine pip4k
WO2025021189A1 (fr) 2023-07-27 2025-01-30 上海拓界生物医药科技有限公司 Dérivé tricyclique fusionné contenant de l'oxygène, son procédé de préparation et son utilisation
WO2025102352A1 (fr) 2023-11-17 2025-05-22 Genentech, Inc Formes salines et solides d'un inhibiteur de cdk
WO2025111845A1 (fr) 2023-11-29 2025-06-05 Genentech, Inc. Formes salines et solides d'un inhibiteur de cdk
TW202539674A (zh) * 2024-03-05 2025-10-16 大陸商浙江同源康醫藥股份有限公司 用作cdk4蛋白激酶抑制劑的化合物及其應用
CN119751339A (zh) * 2024-12-30 2025-04-04 中国科学院长春应用化学研究所 一种六元环状鸟氨酸衍生单体、改性尼龙6及其制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
WO2002072581A2 (fr) 2001-03-08 2002-09-19 Smithkline Beecham Corporation Composes therapeutiques
US20040171630A1 (en) 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
ATE325608T1 (de) 2001-08-13 2006-06-15 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung
ATE407678T1 (de) * 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
JP2005516916A (ja) 2001-12-11 2005-06-09 スミスクライン ビーチャム コーポレーション 抗ヘルペス薬としてのピラゾロ−ピリジン誘導体
IL162838A0 (en) 2002-01-04 2005-11-20 Univ Rockefeller Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
CA2561895A1 (fr) 2004-04-13 2005-10-27 Icagen, Inc. Pyrimidines polycycliques utilises en tant que modulateurs du canal ionique du potassium
JP2008515986A (ja) 2004-10-13 2008-05-15 ワイス Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20100267707A1 (en) 2006-06-22 2010-10-21 Merck Sharp & Dohme Corp. Tyrosine Kinase Inhibitors
CA2654670A1 (fr) 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh Nouveaux composes
EA201001030A1 (ru) 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
UY32203A (es) 2008-10-29 2010-05-31 Astrazeneca Ab Amino pirimidinas y su uso en terapia
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
NZ713361A (en) 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
EP2558092B1 (fr) 2010-04-13 2018-06-27 Novartis AG Combinaison comprenant un inhibiteur de kinase dépendante de cycline 4 ou de kinase dependante de cycline 6 (cdk4/6) et de l'everolimus pour traiter le cancer
PE20130774A1 (es) 2010-07-29 2013-06-26 Rigel Pharmaceuticals Inc Compuestos heterociclicos activadores de ampk y metodos para emplearlos
EP4119551A1 (fr) 2011-07-27 2023-01-18 Astrazeneca AB Composés de 2-(anilino 2,4,5-substitué)pyrimidine
WO2013173506A2 (fr) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Procédé de traitement d'une dégradation musculaire
CA2906157C (fr) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Agents antineoplasiques et antiproliferatifs hautement actifs
WO2014181287A1 (fr) 2013-05-09 2014-11-13 Piramal Enterprises Limited Composés hétérocyclyliques et leurs utilisations
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
CA2927924A1 (fr) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Composes heteroaromatiques utiles pour le traitement des maladies proliferatives
CN104761544B (zh) 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
FR3018704B1 (fr) 2014-03-20 2016-03-18 Rexam Healthcare La Verpillier Dispositif de distribution de liquide comprenant un capuchon de protection.
CN110229142A (zh) 2014-04-04 2019-09-13 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
WO2015161288A1 (fr) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Lactames tricycliques utilisés en tant qu'agents anti-néoplasiques et anti-prolifératifs
CA2954298A1 (fr) 2014-07-24 2016-01-28 Beta Pharma, Inc. Derives de 2-h-indazole en tant qu'inhibiteurs de la kinase dependante de la cycline (cdk) et leurs utilisations therapeutiques
US10241219B2 (en) 2014-07-25 2019-03-26 Westerngeco L.L.C. Sensor device having elongated housing
WO2016015605A1 (fr) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Composés en tant que petites molécules inhibitrices de la cdk et leurs utilisations
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． ターゲティングされたアンドロゲン受容体分解のための化合物および方法
CN111333627B (zh) 2015-03-11 2024-09-13 正大天晴药业集团股份有限公司 作为抗癌药物的取代的2-氢-吡唑衍生物
WO2017017783A1 (fr) 2015-07-28 2017-02-02 三菱電機株式会社 Dispositif d'aide à la conduite
WO2017133701A1 (fr) * 2016-02-06 2017-08-10 Shanghai Fochon Pharmaceutical Co., Ltd. Certains inhibiteurs de protéines kinases
CN107286134B (zh) * 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用
PL3442947T3 (pl) * 2016-04-15 2023-10-02 Epizyme, Inc. Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2
EP3492462B1 (fr) 2016-07-26 2023-08-30 Shenzhen TargetRx, Inc. Composé amino pyrimidine pour inhiber l'activité de la protéine tyrosine kinase
WO2018045957A1 (fr) * 2016-09-07 2018-03-15 江苏豪森药业集团有限公司 Inhibiteur de cdk4/6, son procédé de préparation et son application
WO2018113771A1 (fr) * 2016-12-22 2018-06-28 Betta Pharmaceuticals Co., Ltd Dérivés de benzimidazole, leurs procédés de préparation et leurs utilisations
WO2018121766A1 (fr) * 2016-12-30 2018-07-05 上海医药集团股份有限公司 Composé hétérocyclique fusionné contenant de l'azote, procédé de préparation, intermédiaire, composition et utilisation associés
CN108794452B (zh) * 2017-05-05 2021-05-28 上海时莱生物技术有限公司 具有激酶抑制活性的化合物、其制备方法和用途
EP3658548A1 (fr) 2017-07-28 2020-06-03 Arvinas Operations, Inc. Composés et procédés pour la dégradation ciblée du récepteur des androgènes
CN111094291B (zh) 2017-08-11 2022-06-21 晟科药业（江苏）有限公司 1h-吡唑并[4,3-h]喹唑啉类化合物作为蛋白激酶抑制剂
CN109503573A (zh) * 2017-09-14 2019-03-22 昆明圣加南生物科技有限公司 2-取代苯胺基嘧啶衍生物及其用途
WO2019133864A1 (fr) * 2017-12-29 2019-07-04 Accutar Biotechnology Inhibiteurs doubles de parp1 et de cdk
CN111989099A (zh) * 2018-01-29 2020-11-24 贝塔制药有限公司 作为cdk4和cdk6抑制剂的2h-吲唑衍生物及其治疗用途
CN110156754B (zh) 2018-02-10 2023-10-03 杭州百诚医药科技股份有限公司 一种三取代嘧啶衍生物对蛋白激酶的抑制作用
CN108484606B (zh) 2018-03-16 2020-03-06 江南大学 一种嘧啶并[4,5-f]喹唑啉类化合物及其应用
CN113166110B (zh) 2018-12-12 2023-08-11 暨南大学 2-氨基嘧啶类化合物及其应用
JP2022517723A (ja) 2018-12-19 2022-03-10 キーセラ・（スーチョウ）・ファーマシューティカルズ・カンパニー・リミテッド Ｃｄｋ阻害剤としての大環状化合物、その製造方法及びその医薬品における応用
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
MA55909A (fr) 2019-05-05 2022-03-16 Qilu Regor Therapeutics Inc Inhibiteurs de cdk
TWI869412B (zh) * 2019-06-14 2025-01-11 學校法人關西學院 多環芳香族化合物或多環芳香族化合物的多聚體、反應性化合物、高分子化合物或高分子交聯體、懸掛型高分子化合物或懸掛型高分子交聯體、有機元件用材料、組成物、有機電致發光元件、顯示裝置或照明裝置及多環芳香族化合物或多環芳香族化合物的多聚體的製造方法
CN112513029B (zh) 2019-06-21 2023-10-24 上海翰森生物医药科技有限公司 含氮芳基磷氧化物类衍生物、其制备方法和应用
US12398132B2 (en) 2019-07-10 2025-08-26 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents
US20230118053A1 (en) 2020-03-27 2023-04-20 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Combination of anti-her2 antibody and cdk inhibitior for tumor treatment

Also Published As

Publication number Publication date
JP2023525005A (ja) 2023-06-14
WO2021226140A1 (fr) 2021-11-11
MX2021013531A (es) 2022-02-11
CN115803327B (zh) 2024-02-13
JP2025128182A (ja) 2025-09-02
IL287767A (en) 2022-01-01
AU2021268648A1 (en) 2023-01-19
JP2022531687A (ja) 2022-07-08
WO2020224568A1 (fr) 2020-11-12
CA3138973A1 (fr) 2020-11-12
EA202193015A1 (ru) 2022-03-17
MX2025008591A (es) 2025-08-01
AU2020269469B2 (en) 2026-01-29
CN114364675A (zh) 2022-04-15
CN120040446A (zh) 2025-05-27
BR112021022105A2 (pt) 2021-12-28
PH12021552805A1 (en) 2022-12-05
TW202545942A (zh) 2025-12-01
US20250275971A1 (en) 2025-09-04
US12285429B2 (en) 2025-04-29
EP4146647B1 (fr) 2026-04-15
KR20220004755A (ko) 2022-01-11
SG11202112229UA (en) 2021-12-30
AU2026200999A1 (en) 2026-03-05
CN118406049A (zh) 2024-07-30
US20240033264A1 (en) 2024-02-01
US20250325544A1 (en) 2025-10-23
AU2026201001A1 (en) 2026-03-05
CO2021016504A2 (es) 2022-01-17
MX2025008589A (es) 2025-08-01
US20250064806A1 (en) 2025-02-27
JP2025090693A (ja) 2025-06-17
TWI895410B (zh) 2025-09-01
KR20260004524A (ko) 2026-01-08
EP3966213A4 (fr) 2023-04-19
US20250281487A1 (en) 2025-09-11
IL287767B2 (en) 2025-02-01
CL2021002903A1 (es) 2022-07-08
US20220296595A1 (en) 2022-09-22
US20240066031A1 (en) 2024-02-29
TWI875756B (zh) 2025-03-11
MX2025008593A (es) 2025-08-01
US20250275972A1 (en) 2025-09-04
IL315588A (en) 2024-11-01
TW202108572A (zh) 2021-03-01
US20230174512A1 (en) 2023-06-08
JP7689984B2 (ja) 2025-06-09
IL287767B1 (en) 2024-10-01
JP7671425B2 (ja) 2025-05-02
AU2020269469A1 (en) 2021-12-09
TW202521536A (zh) 2025-06-01
TW202144351A (zh) 2021-12-01
EP4146647A1 (fr) 2023-03-15
EP3966213A1 (fr) 2022-03-16
CN115803327A (zh) 2023-03-14
KR102898876B1 (ko) 2025-12-12

Similar Documents

Publication Publication Date Title
MA55909A (fr) Inhibiteurs de cdk
EP4007752C0 (fr) Inhibiteurs de kif18a
EP4007753C0 (fr) Inhibiteurs de kif18a
IL283639A (en) Kif18a inhibitors
MA54550A (fr) Inhibiteurs de kif18a
EP4007756C0 (fr) Inhibiteurs de kif18a
DK3740479T3 (da) Dna-pk-hæmmere
EP3801503A4 (fr) Inhibiteurs de sarm1
EP3843714A4 (fr) Inhibiteurs de cd73
MA53287A (fr) Inhibiteurs de prmt5
PT3980417T (pt) Inibidores de prmt5
MA52413A (fr) Inhibiteurs de cd73
MA52813A (fr) Inhibiteurs de sarm1
EP3980011A4 (fr) Inhibiteurs de sarm1
EP3761992A4 (fr) Inhibiteurs d'arginase
EP3856176A4 (fr) Inhibiteurs de vap-1
EP3787635A4 (fr) Inhibiteurs de cd73
EP3817736A4 (fr) Inhibiteurs de pikfyve
EP3999517A4 (fr) Inhibiteurs de cd73
EP3801499A4 (fr) Inhibiteurs de sarm1
EP3938358A4 (fr) Inhibiteurs de rad51
EP4077282A4 (fr) Inhibiteurs de prmt5
MA55477A (fr) Inhibiteurs de hpk1
EP3856194A4 (fr) Inhibiteurs de vap-1
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors